JP2004532896A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532896A5
JP2004532896A5 JP2003507548A JP2003507548A JP2004532896A5 JP 2004532896 A5 JP2004532896 A5 JP 2004532896A5 JP 2003507548 A JP2003507548 A JP 2003507548A JP 2003507548 A JP2003507548 A JP 2003507548A JP 2004532896 A5 JP2004532896 A5 JP 2004532896A5
Authority
JP
Japan
Prior art keywords
leu
compound
group
val
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003507548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532896A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2002/000975 external-priority patent/WO2003001204A2/en
Publication of JP2004532896A publication Critical patent/JP2004532896A/ja
Publication of JP2004532896A5 publication Critical patent/JP2004532896A5/ja
Pending legal-status Critical Current

Links

JP2003507548A 2001-06-22 2002-06-25 I型糖尿病の診断及び治療 Pending JP2004532896A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29975401P 2001-06-22 2001-06-22
PCT/CA2002/000975 WO2003001204A2 (en) 2001-06-22 2002-06-25 Type 1 diabetes diagnostics and therapeutics

Publications (2)

Publication Number Publication Date
JP2004532896A JP2004532896A (ja) 2004-10-28
JP2004532896A5 true JP2004532896A5 (enExample) 2006-01-05

Family

ID=23156146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003507548A Pending JP2004532896A (ja) 2001-06-22 2002-06-25 I型糖尿病の診断及び治療

Country Status (5)

Country Link
US (1) US20050129617A1 (enExample)
EP (1) EP1399740A2 (enExample)
JP (1) JP2004532896A (enExample)
CA (1) CA2449990A1 (enExample)
WO (1) WO2003001204A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479482B2 (en) * 2001-11-21 2009-01-20 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto
EP1846438A2 (en) * 2005-01-31 2007-10-24 Leiden University Medical Center Methods and means for use in diagnostics and treatment of diabetes
DK2131856T3 (da) * 2007-03-07 2014-12-15 Uti Limited Partnership Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US20140068487A1 (en) * 2012-09-05 2014-03-06 Roche Diagnostics Operations, Inc. Computer Implemented Methods For Visualizing Correlations Between Blood Glucose Data And Events And Apparatuses Thereof
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
US8993008B1 (en) 2013-12-16 2015-03-31 Umm Al-Qura University Herbal composition for treating diabetes
DE102015003676A1 (de) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
CN111741746A (zh) 2017-11-29 2020-10-02 乌第有限合伙公司 治疗自身免疫性疾病的方法
CN108152503A (zh) * 2017-12-19 2018-06-12 上海澜帆实业有限公司 酶联免疫斑点印迹的自身免疫检测试剂盒及其操作流程

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
US6039947A (en) * 1987-06-24 2000-03-21 Autoimmune, Inc. Peptides derived from immunodominant epitopes of myelin basic protein
US5147289A (en) * 1990-03-29 1992-09-15 Therakos, Inc Non-specific immune system enhancement
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US5651993A (en) * 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
EP1094828A4 (en) * 1998-05-07 2005-01-26 Univ California USE OF TARGETED, NEGLIGATED TISSUE ANTIGENS TO MODULATE IMMUNE REACTIONS
AU7033400A (en) * 1999-08-30 2001-03-26 Jehad Mikhaiel Charo Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopesof mycobacterial heat shock protein 65

Similar Documents

Publication Publication Date Title
JP2004532896A5 (enExample)
Robbins et al. Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients
Martin et al. T cell recognition of haptens, a molecular view
AU766545B2 (en) Novel anti-diabetic peptides
Putnam et al. Structure and evolution of kappa and lambda light chains
US5807552A (en) Compositions for conferring immunogenicity to a substance and uses thereof
CA2516702A1 (en) Modified t cell receptor linked by disulphide bond between constant domain cysteine residues
JP2002206000A5 (enExample)
RU2020136305A (ru) Производные gip и пути их применения
TW200835513A (en) HLA-A* 1101-restricted WT1 peptide and pharmaceutical composition comprising the same
Low et al. Structure, function, and evolutionary relationships of Fc domains of human immunoglobulins A, G, M, and E
Chance Amino acid sequences of proinsulins and intermediates
EA003944B1 (ru) Способы лечения диабета с помощью пептидных аналогов инсулина
EA012507B1 (ru) Высокоаффинные мелан-а т-клеточные рецепторы
Rutishauser et al. Amino acid sequence of the Fc region of a human gamma G-immunoglobulin.
KR20090059152A (ko) 쿠프레독신으로 암을 예방하는 조성물과 방법
CZ292454B6 (cs) Peptid schopný neutralizovat nebo modulovat produkci anti-myelinového bazického proteinu a jeho použití při léčbě sklerózy multiplex
Bierwagen et al. Strong interactions between Salp15 homologues from the tick I. ricinus and distinct types of the outer surface OspC protein from Borrelia
EP0815136B1 (en) Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
JP2006515744A5 (enExample)
Joshi et al. Flexibility in MHC and TCR recognition: degenerate specificity at the T cell level in the recognition of promiscuous Th epitopes exhibiting no primary sequence homology
AU2001285427B2 (en) Stress proteins and peptides and methods of use thereof
Chen et al. Identification and characterization of a T cell-inducing epitope of bovine ribonuclease that can be restricted by multiple class II molecules
CN111454371A (zh) PDL1-pHLIP、制备方法及其在治疗自身免疫病中的应用
Hamada et al. Molecular interactions of surface protein peptides of Streptococcus gordonii with human salivary components